| pubmed-article:8639789 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8639789 | lifeskim:mentions | umls-concept:C0033325 | lld:lifeskim |
| pubmed-article:8639789 | lifeskim:mentions | umls-concept:C0032854 | lld:lifeskim |
| pubmed-article:8639789 | lifeskim:mentions | umls-concept:C0334634 | lld:lifeskim |
| pubmed-article:8639789 | lifeskim:mentions | umls-concept:C0010819 | lld:lifeskim |
| pubmed-article:8639789 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
| pubmed-article:8639789 | lifeskim:mentions | umls-concept:C0205419 | lld:lifeskim |
| pubmed-article:8639789 | lifeskim:mentions | umls-concept:C0079419 | lld:lifeskim |
| pubmed-article:8639789 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:8639789 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:8639789 | lifeskim:mentions | umls-concept:C1561558 | lld:lifeskim |
| pubmed-article:8639789 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:8639789 | pubmed:dateCreated | 1996-7-16 | lld:pubmed |
| pubmed-article:8639789 | pubmed:abstractText | Mutations of the p53 tumor suppressor gene have been described in several subtypes of non-Hodgkin's lymphoma, but the incidence of p53 mutations in mantle cell lymphoma (MCL) is unknown. We hypothesized that cases of MCL with a variant or high-grade cytology would have a higher likelihood of p53 mutations than typical MCL. We were also interested in the prognostic significance of p53 mutations in MCL. Therefore, a series of 53 well-characterized cases of MCL with DNA from 62 tissue samples were analyzed by the polymerase chain reaction with denaturing gradient gel electrophoresis for exons 5-8 of p53. Immunoperoxidase studies with the antibody DO-7 to p53 protein were also performed on frozen sections. We found mutations of the p53 gene in 8 of the 53 cases (15%) of MCL. Missense mutations predominated, and 50% of the mutations occurred at known p53 hotspot codons. Of 21 cases with variant cytology (ie, anaplastic or blastic), 6 (28.6%) had p53 mutations as compared with only 2 of 32 cases (6.3%) with typical MCL cytology (P = .05), and p53 mutations preceded the development of variant cytology in 2 patients. Overexpression of p53 protein was observed in 6 of the 8 cases (75%) with p53 mutations and in none of the 45 wild-type cases. The median survival of the cases with mutant p53 was only 1.3 years (all died), whereas the median survival of cases with germline p53 was 5.1 years (P = .023). These results suggest that mutations of p53 may be one mechanism involved in the development of variant forms of MCL and indicate that p53 mutations in MCL predict a poor prognosis. | lld:pubmed |
| pubmed-article:8639789 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8639789 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8639789 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8639789 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8639789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8639789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8639789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8639789 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8639789 | pubmed:month | May | lld:pubmed |
| pubmed-article:8639789 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:8639789 | pubmed:author | pubmed-author:PedersenAA | lld:pubmed |
| pubmed-article:8639789 | pubmed:author | pubmed-author:AndersonJ RJR | lld:pubmed |
| pubmed-article:8639789 | pubmed:author | pubmed-author:ChanW CWC | lld:pubmed |
| pubmed-article:8639789 | pubmed:author | pubmed-author:WeisenburgerD... | lld:pubmed |
| pubmed-article:8639789 | pubmed:author | pubmed-author:GreinerT CTC | lld:pubmed |
| pubmed-article:8639789 | pubmed:author | pubmed-author:MoynihanM JMJ | lld:pubmed |
| pubmed-article:8639789 | pubmed:author | pubmed-author:LytleD MDM | lld:pubmed |
| pubmed-article:8639789 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8639789 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8639789 | pubmed:volume | 87 | lld:pubmed |
| pubmed-article:8639789 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8639789 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8639789 | pubmed:pagination | 4302-10 | lld:pubmed |
| pubmed-article:8639789 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:meshHeading | pubmed-meshheading:8639789-... | lld:pubmed |
| pubmed-article:8639789 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8639789 | pubmed:articleTitle | p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. | lld:pubmed |
| pubmed-article:8639789 | pubmed:affiliation | Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198-3135, USA. | lld:pubmed |
| pubmed-article:8639789 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8639789 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8639789 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:8639789 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8639789 | lld:pubmed |
